C. Schrey

Minimum clinically important difference analysis confirms the efficacy of IgPro10 in CIDP: the PRIMA trial

W. Robberecht, B. Tackenberg, C. Sommer, 2017, Journal of the peripheral nervous system : JPNS.

Smart Institutions: Concept, Index, and Framework Conditions

H. Wiesmeth, D. Häckl, C. Schrey, 2020, Handbook of Smart Cities.

Assessing patients' acceptable and realised distances to determine accessibility standards for the size of catchment areas in outpatient care.

Carsta Militzer-Horstmann, L. Sundmacher, Laura Schang, 2022, Health policy.

Efficacy and safety of IVIG in CIDP: Combined data of the PRIMA and PATH studies

G. L. Masson, D. Yarnitsky, M. Valis, 2019, Journal of the peripheral nervous system : JPNS.

Effectiveness and safety of opicapone in Parkinson’s disease patients with motor fluctuations: the OPTIPARK open-label study

D. Gruber, A. Kupsch, H. Reichmann, 2020, Translational Neurodegeneration.

The natural history of primary progressive multiple sclerosis: insights from the German NeuroTransData registry

R. Fleischer, C. Hofer, H. Peters, 2023, BMC Neurology.

Effectiveness and safety of opicapone in Parkinson’s disease patients with motor fluctuations: the OPTIPARK open-label study

O. Witte, D. Gruber, A. Kupsch, 2020, Translational Neurodegeneration.

Maximum Simulated Likelihood: Don't Stop 'Til You Get Enough?

Carsta Militzer-Horstmann, Christopher Schrey, Tobias Schäffer, 2019, FedCSIS.

Effectiveness and safety of opicapone in Parkinson’s disease patients with motor fluctuations: the OPTIPARK open-label study

O. Witte, D. Gruber, A. Kupsch, 2020, Translational Neurodegeneration.